|
Dec 06, 2021
|
Evrysdi® Distinguished by Two Prestigious Awards for Outstanding Innovation in Drug Discovery
SOUTH PLAINFIELD, N.J. , Dec. 6, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi ® (risdiplam) has received multiple awards that recognize it as one of the most innovative therapies of 2021 and for its life-saving impact.
|
|
|
Dec 02, 2021
|
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J. , Dec. 2, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 29, 2021 , the company approved non-statutory stock options to purchase an aggregate of 83,750 shares of its common stock and 21,550 restricted stock units ("RSUs"), each
|
|
|
Nov 16, 2021
|
PTC Therapeutics to Participate at Upcoming Virtual Investor Conference
SOUTH PLAINFIELD, N.J. , Nov. 16, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the 4th Annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 30 at 8:25 a.m. ET . The presentation will be webcast live on the
|
|
|
Oct 28, 2021
|
PTC Therapeutics Provides a Corporate Update and Reports Third Quarter 2021 Financial Results
- Total quarterly revenue of $139 million; 17% increase over third quarter 2020 - - Raises 2021 DMD franchise revenue guidance to $400-$420M from $370-$390M - - Continues to advance robust clinical pipeline by initiating a fifth registration-directed trial, APHENITY Phase 3 trial of PTC923 in
|
|
|
Oct 26, 2021
|
PTC Therapeutics to Participate at Upcoming Virtual Investor Conference
SOUTH PLAINFIELD, N.J. , Oct. 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Credit Suisse 30th Annual Healthcare Conference on Tuesday, Nov. 9 at 8:00 a.m. ET . The presentation will be webcast live on the
|
|
|
Oct 25, 2021
|
PTC Announces Expansion of Translarna™ Label to Include Ambulatory Patients as Young as 2 Years Old in Brazil
SOUTH PLAINFIELD, N.J. , Oct. 25, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Brazilian National Health Surveillance Agency , ANVISA (Agência Nacional de Vigilância Sanitária), has approved the expansion of the indication of Translarna™ (ataluren) to include
|
|
|
Oct 14, 2021
|
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2021 Financial Results
SOUTH PLAINFIELD, N.J. , Oct. 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2021 financial results and provide an update on the company's business and outlook on Thursday, Oct.
|
|
|
Oct 14, 2021
|
PTC Therapeutics Celebrates Opening of Gene Therapy Manufacturing Facility
-- Expansion in New Jersey supports company's robust gene therapy pipeline to address devastating rare disorders -- SOUTH PLAINFIELD, N.J. , Oct. 14, 2021 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) will host a ribbon-cutting ceremony to recognize the official opening of its new gene
|
|
|
Oct 11, 2021
|
Tegsedi® Receives Innovative Drug Category Pricing in Brazil
SOUTH PLAINFIELD, N.J. , Oct. 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Tegsedi ® (inotersen) has successfully received Category 1 classification from Câmara de Regulação do Mercado de Medicamentos - CMED (Drug Market Regulation Chamber) in Brazil .
|
|
|
Sep 29, 2021
|
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J. , Sept. 29, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept. 22, 2021, the company approved non-statutory stock options to purchase an aggregate of 51,400 shares of its common stock and 18,790 restricted stock units ("RSUs"), each
|
|
